pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Moderate
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
CC-99282-NHL-001
Phase 2 · small molecule · Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
CC-99282-NHL-001 for Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code CC-99282-NHL-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Celgene Europe Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
- Status
- active
- Trials
- 1